BLACK FRIDAY

ADVFN

Celebrating 25 years Est 1999-2024

Save up to 65%* for Small Cap Pro

1 year 40%, 2 years 50% and *3 years 65%

*Across 3 years $2158.56 only $755.50

ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,969.34
0.35%
US Tech 100
20,266.40
0.33%
Dow Jones
44,296.51
0.97%
Brent Oil
74.195
-0.77%
Bitcoin
98,386.00
0.35%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Europe
  5. EU

  6. Vivoryon Therapeut (VVY) Quote

Vivoryon Therapeut

Vivoryon Therapeut (VVY)

EU
2.02
0.00
(0.00%)
Closed November 25 11:30AM
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
2.02
Bid
2.03
Ask
2.04
Volume
0.00
0.00 Day's Range 0.00
0.41 52 Week Range 9.93
Market Cap
-
Previous Close
2.02
Open
-
Last Trade
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
188,295
Shares Outstanding
0.00
Dividend Yield
-
PE Ratio
0.00
Earnings Per Share (EPS)
-
Revenue
-3.62M
Net Profit
-28.34M

About Vivoryon Therapeut

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.vivoryon.com
Headquarters
Halle, Deu
Founded
-
Vivoryon Therapeut is listed in the Biological Pds,ex Diagnstics sector of the Euronext with ticker VVY. The last closing price for Vivoryon Therapeut was 2.02 €. Over the last year, Vivoryon Therapeut shares have traded in a share price range of 0.41 € to 9.93 €.

Vivoryon Therapeut currently has 0 shares outstanding.

Ask ADVFN Intelligence (AI)

VVY Latest News

More News

Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of Varoglutamstat on Kidney Function at ASN Kidney Week 2024

Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of Varoglutamstat on Kidney Function at ASN Kidney Week 2024 Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of...

October 26 2024
UK Regulatory

Vivoryon Therapeutics N.V. Announces Late-breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024

Vivoryon Therapeutics N.V. Announces Late-breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024 Halle (Saale) / Munich, Germany, October 11, 2024 – Vivoryon...

October 11 2024
UK Regulatory

Vivoryon Therapeutics N.V. Shares Highlights from Virtual Kidney Disease KOL Event

Vivoryon Therapeutics N.V. Shares Highlights from Virtual Kidney Disease KOL Event Halle (Saale) / Munich, Germany, October 1, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY;...

October 01 2024
UK Regulatory

Vivoryon Therapeutics N.V. Reports H1 2024 Progress Marked by Compelling Kidney Function Data and Execution of Strategy to Advance Varoglutamstat in Kidney Disease

Vivoryon Therapeutics N.V. Reports H1 2024 Progress Marked by Compelling Kidney Function Data and Execution of Strategy to Advance Varoglutamstat in Kidney Disease Vivoryon Therapeutics N.V...

September 12 2024
UK Regulatory

Vivoryon Therapeutics N.V. Announces Completion of Share Capital Reduction and Change to Articles of Association

Vivoryon Therapeutics N.V. Announces Completion of Share Capital Reduction and Change to Articles of Association Vivoryon Therapeutics N.V. Announces Completion of Share Capital Reduction and...

September 05 2024
UK Regulatory

Vivoryon Therapeutics N.V. to Report Half Year 2024 Financial Results on September 12, and to Host KOL Event on September 30, 2024

Vivoryon Therapeutics N.V. to Report Half Year 2024 Financial Results on September 12, and to Host KOL Event on September 30, 2024 Vivoryon Therapeutics N.V. to Report Half Year 2024 Financial...

September 05 2024
UK Regulatory

Vivoryon Therapeutics N.V. Announces New Data Showing Unique Treatment Effects of Varoglutamstat on Kidney Function in Patients with Diabetes and Outlines Proposed Clinical Development Plan in Diabetic Kidney Disease

Vivoryon Therapeutics N.V. Announces New Data Showing Unique Treatment Effects of Varoglutamstat on Kidney Function in Patients with Diabetes and Outlines Proposed Clinical Development Plan in...

July 18 2024
UK Regulatory

Vivoryon Therapeutics N.V. to Host R&D Update Call on July 18, 2024 Focused on Progress in Kidney Disease

Vivoryon Therapeutics N.V. to Host R&D Update Call on July 18, 2024 Focused on Progress in Kidney Disease Vivoryon Therapeutics N.V. to Host R&D Update Call on July 18, 2024 Focused on...

July 09 2024
UK Regulatory

Vivoryon Therapeutics N.V. to Host R&D Update Call on July 18, 2024 Focused on Progress in Kidney Disease

Vivoryon Therapeutics N.V. to Host R&D Update Call on July 18, 2024 Focused on Progress in Kidney Disease Halle (Saale) / Munich, Germany, July 9, 2024 - Vivoryon Therapeutics N.V. (Euronext...

July 09 2024
GlobeNewswire Inc.

Vivoryon Therapeutics N.V. Reports Outcome of 2024 Annual General Meeting

Vivoryon Therapeutics N.V. Reports Outcome of 2024 Annual General Meeting Vivoryon Therapeutics N.V. Reports Outcome of 2024 Annual General Meeting Halle (Saale) / Munich, Germany, June 21...

June 21 2024
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.0150.748129675812.0052.1351.944817442.04991723DE
4-0.49-19.52191235062.512.511.944943612.2110302DE
12-0.16-7.339449541282.182.9951.8241882952.32179979DE
26-0.48-19.22.56.31.3245365802.62084215DE
52-6.18-75.36585365858.29.930.415410272.0477163DE
156-16.23-88.931506849318.2520.6350.412208043.90915103DE
260-3.26-61.74242424245.2823.250.411709545.1716971DE

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
ABEOABEO SA
9.94 €
(0.00%)
0
ABCAABC Arbitrage
4.755 €
(0.00%)
0
ABAb Science
0.80 €
(0.00%)
0
AALBAalberts NV
34.10 €
(0.00%)
0
AAAAlan Allman Associates
4.20 €
(0.00%)
0
ABEOABEO SA
9.94 €
(0.00%)
0
ABCAABC Arbitrage
4.755 €
(0.00%)
0
ABAb Science
0.80 €
(0.00%)
0
AALBAalberts NV
34.10 €
(0.00%)
0
AAAAlan Allman Associates
4.20 €
(0.00%)
0
ABEOABEO SA
9.94 €
(0.00%)
0
ABCAABC Arbitrage
4.755 €
(0.00%)
0
ABAb Science
0.80 €
(0.00%)
0
AALBAalberts NV
34.10 €
(0.00%)
0
AAAAlan Allman Associates
4.20 €
(0.00%)
0

Discussion

View Full Feed
martyDg martyDg 10 minutes ago
Blame blame blame blame...It was never LP course of actions the reason why where in this low pps. It was never LP's decision we're not filing BLA to FDA.
NWBO
tm3141 tm3141 12 minutes ago
tomorrow is going to be a big up day for f&f, even if the market is down. and it's just the start of the bull run. 
FNMA
The Danish Dude The Danish Dude 13 minutes ago
Great find by Peter Brit on X

From the team that brought you the 14 year long combo trial with DCvax-L and poly-iclc (so sorry ex, that the Nature article in the Ethics declaration stated the dendritic cells used was DCvax-L, just as Linda Liau also stated at the webinar in 2022 with
NWBO
skitahoe skitahoe 14 minutes ago
Marty, what would the good of a BLA do if when the FDA asked to inspect the commercial production facility you had nothing to show. The EDEN is the key to commercial production and until they know it will be approved in time to have a commercial production facility ready for inspection, a BLA simpl
NWBO
Zorax Zorax 19 minutes ago
Makes perfect sense to me. Obviously it's the intention.
Delay everything until sworn in and then claim they don't have the time to confirm and demand no confirmation appointments.
shitface is still going to try to force a recess to get around the vetting of course.

I do
martyDg martyDg 19 minutes ago
It's Galadon Gaming.... with so much followers but can't get them to buy NWBO shares. He's been on this for a while. None of his followers buying it.
NWBO
SunnySage38 SunnySage38 21 minutes ago
https://support.google.com/phoneapp/thread/309687377?hl=en¬ify=new&sjid=6242442536883052726-NA

https://support.google.com/phoneapp/thread/309687377?hl=en¬ify=new&sjid=6242442536883052726-NA

https://support.google.com/phoneapp/thread/309687377?hl=en¬ify=new&sjid
BDEZ BDEZ 23 minutes ago
FL Sheriff Keith Pearson just posted this

https://x.com/EndWokeness/status/1860844773881291108
martyDg martyDg 24 minutes ago
If we are naive then explain why management doesn't have BLA submission for FDA? Too busy with all patent application & combo trials which possibly bring revenue far in the distant future compared to L which can generate revenue in the near future. No matter how you twist this is just plain stupid.
NWBO
Evaluate Evaluate 28 minutes ago
Wow: big weekly gain!
Palladyne AI and Red Cat Expand Partnership for Teal Drones
Nov 20, 2024
https://investor.palladyneai.com/news-releases/news-release-details/palladyne-ai-and-red-cat-expand-partnership-teal-drones

I bought some Palladyne on Nov 20, and sold 2
PDYN
BDEZ BDEZ 29 minutes ago
Tom Homan is already receiving death threats and confirms his family has had to evacuate their home

https://x.com/DrewHLive/status/1860886411735347329
SovereignCyclops62 SovereignCyclops62 30 minutes ago
https://lacdmhowr.powerappsportals.us/forums/general-discussion/39220a80-f7aa-ef11-b542-001dd8097a1a
https://lacdmhowr.powerappsportals.us/forums/general-discussion/39220a80-f7aa-ef11-b542-001dd8097a1a
https://lacdmhowr.powerappsportals.us/forums/general-discussion/39220a80-f7aa-ef11-b
MoneyMaker111 MoneyMaker111 31 minutes ago
GME: $30 today (buy now, ask questions later)

$GME ( hyper bullish / apish )
#GME ( hyper bullish / apish )
GME
martyDg martyDg 34 minutes ago
okay, gullible cult followers of LP. You're the greater loser here bragging useless JA that doesn't help speed up the process of approval.
So why the fuc* they're not applying for FDA? Instead of waiting their asses for MAA and doing something relevant to something that's really going to brin
NWBO
WandererNavigator34 WandererNavigator34 34 minutes ago
https://lacdmhowr.powerappsportals.us/forums/general-discussion/3769cafb-e3aa-ef11-b542-001dd8097a1a
https://lacdmhowr.powerappsportals.us/forums/general-discussion/9899fecd-e4aa-ef11-b542-001dd8097a1a
https://lacdmhowr.powerappsportals.us/forums/general-discussion/8d987af9-e4aa-ef11
BDEZ BDEZ 37 minutes ago
If it’s proved that Ruben Gallego got some of that Ukraine war money, that will be a huge story! Especially since McConnell
didn’t give a dime of support to Kari Lake. The corruption in Washington is so deep! It’s time to weed it all out

https://x.com/BenBergquam/status/186085
jeunke22 jeunke22 37 minutes ago
This Lightmatter and Global Foundries cooperation is part of the photonic ecosystem coming together and meant to connect CPU’s and GPU’s.
Different market, but part of the total eco system to support AI the need for increased bandwidth in datacenters, The Passage platform uses 3D silicon pho
LWLG
JoeForkeyBolo JoeForkeyBolo 39 minutes ago
One more update on AIM testing results for UPRO over 5-year and 10-year periods.

TEST 3
5 years: 11/15/19 – 11/15/24
Cash depletion allowed, Black Swan Rule utilized
Initial Investment: $10,000 @ 50% equity, 50% cash
Buy SAFE: 10%
Sell SAFE: 10%
MarauderRealm57 MarauderRealm57 39 minutes ago
https://lacdmhowr.powerappsportals.us/forums/general-discussion/98536d79-f7aa-ef11-b542-001dd8097a1a
https://lacdmhowr.powerappsportals.us/forums/general-discussion/98536d79-f7aa-ef11-b542-001dd8097a1a
https://lacdmhowr.powerappsportals.us/forums/general-discussion/98536d79-f7aa-ef11-b
Jack_of_All_Trades Jack_of_All_Trades 42 minutes ago
Nobody f@cking cares about you at all.

RDAR
RDAR
gitreal gitreal 43 minutes ago
I present facts and reliable sources....and it seems to trigger you. Maybe go grab an adult beverage, get some sleep, or do some breathing exercises. Or all three.
NBRI

Your Recent History

EU
VVY
Vivoryon Therapeut
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved

BLACK FRIDAY

ADVFN

Celebrating 25 years Est 1999-2024

Save up to 60%* for Ultimate Trader

1 year 40%, 2 years 50% and *3 years 60%

*Across 3 years $3395.52 only $1358.21